JPMorgan Chase & Co. set a €104.00 ($120.93) price objective on Merck KGaA (FRA:MRK) in a report published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other brokerages also recently commented on MRK. Deutsche Bank set a €104.00 ($120.93) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Monday, November 18th. Goldman Sachs Group set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the company a sell rating in a research report on Tuesday, December 3rd. HSBC set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Wednesday, November 27th. Sanford C. Bernstein set a €114.00 ($132.56) price target on shares of Merck KGaA and gave the stock a neutral rating in a report on Thursday, November 14th. Finally, Nord/LB set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the company a neutral rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of €103.07 ($119.84).
FRA:MRK opened at €104.35 ($121.34) on Friday. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72). The business has a 50 day moving average price of €106.82 and a 200-day moving average price of €98.03.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: What is a death cross?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.